The clinical outcomes of older individuals, especially those with FLT3-ITD AML, remain unsatisfactory due to frequent comorbid conditions and, in particular, the genetic characteristics of the underlying disease. This evidence concerns the gene FLT3 and acute myeloid leukemia.